Dual Antiplatelet Therapy in Coronary Artery Disease
Author:
Funder
AstraZeneca Pharma India
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine
Link
https://link.springer.com/content/pdf/10.1007/s40119-020-00197-0.pdf
Reference41 articles.
1. Chan MY, Du X, Eccleston D, et al. Acute coronary syndrome in the Asia-Pacific region. Int J Cardiol. 2016;1(202):861–9.
2. Vedanthan R, Seligman B, Fuster V. Global perspective on acute coronary syndrome: a burden on the young and poor. Circ Res. 2014;114(12):1959–75. https://doi.org/10.1161/CIRCRESAHA.114.302782.
3. Ohira T, Iso H. Cardiovascular disease epidemiology in Asia. Circ J. 2013;77(7):1646–52.
4. Wilson SJ, Newby DE, Dawson D, et al. Duration of dual antiplatelet therapy in acute coronary syndrome. Heart. 2017;103(8):573–80.
5. Degrauwe S, Pilgrim T, Aminian A, et al. Dual antiplatelet therapy for secondary prevention of coronary artery disease. Open Heart. 2017;4(2):e000651.
Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The impact of anti-thrombotic therapy on bleeding outcomes and thrombosis following laparoscopic cholecystectomy: a meta-analysis;Updates in Surgery;2024-08-02
2. Sex disparity of DAPT noncompliance in patients with left main stem PCI with DES;Medicine;2024-06-28
3. Effect of pharmacogenomics - oriented Dual Antiplatelet Therapy Followed by P2Y12 receptor inhibitors/Aspirin on Cardiovascular and Bleeding Events in ACS Patients: A Trial Protocol;2024-06-12
4. Ticagrelor monotherapy after a short course of dual antiplatelet therapy with ticagrelor plus aspirin following percutaneous coronary intervention in patients with versus without diabetes mellitus: a meta-analysis of randomized trials;BMC Cardiovascular Disorders;2024-03-19
5. Results of Preclinical Studies of 4-(2-(4-nitrophenyl)-2-oxoethyl)-1-(thietane-3-yl)-1H-1,2,4-triazole-4-th Bromide in Relation to the Hemostasis System <i>in vivo</i>;Drug development & registration;2024-02-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3